Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has provided an update.
Immutep Limited announced that data from its EFTISARC-NEO Phase II trial will be presented at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting. This trial is the first to evaluate eftilagimod alpha in a neoadjuvant setting combined with radiotherapy and pembrolizumab for soft tissue sarcoma, an orphan disease with significant unmet medical needs. The trial, conducted in Poland and funded by the Polish government, could have implications for the treatment of soft tissue sarcoma, potentially improving outcomes in a field with poor prognosis.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.46 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), utilizing its ability to modulate the immune response. Immutep aims to provide innovative treatment options for patients and maximize shareholder value.
YTD Price Performance: -35.62%
Average Trading Volume: 2,878,369
Technical Sentiment Signal: Sell
Current Market Cap: A$344.9M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.